Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C; German Acute Myeloid Leukaemia Cooperative Group; Study Alliance Leukemia Investigators. Krug U, et al. Among authors: heinecke a. Lancet. 2010 Dec 11;376(9757):2000-8. doi: 10.1016/S0140-6736(10)62105-8. Epub 2010 Dec 3. Lancet. 2010. PMID: 21131036
Treatment of older patients with AML.
Büchner T, Berdel WE, Wörmann B, Schoch C, Haferlach T, Schnittger S, Kern W, Aul C, Lengfelder E, Schumacher A, Reichle A, Staib P, Balleisen L, Eimermacher H, Grüneisen A, Rasche H, Sauerland MC, Heinecke A, Mesters RM, Serve HL, Kienast J, Hiddemann W. Büchner T, et al. Among authors: heinecke a. Crit Rev Oncol Hematol. 2005 Nov;56(2):247-59. doi: 10.1016/j.critrevonc.2004.09.010. Epub 2005 Oct 21. Crit Rev Oncol Hematol. 2005. PMID: 16246568 Review.
Maintenance for acute myeloid leukemia revisited.
Büchner T, Krug U, Berdel WE, Heinecke A, Sauerland MC, Wörmann B, Hiddemann W. Büchner T, et al. Among authors: heinecke a. Curr Treat Options Oncol. 2007 Aug;8(4):296-304. doi: 10.1007/s11864-007-0041-1. Curr Treat Options Oncol. 2007. PMID: 18058075 Review.
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W. Büchner T, et al. Among authors: heinecke a. J Clin Oncol. 2009 Jan 1;27(1):61-9. doi: 10.1200/JCO.2007.15.4245. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047294 Clinical Trial.
Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis.
Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heinecke A, Ligges S, Sauer T, Tschanter P, Thoennissen GB, Berning B, Kolb HJ, Reichle A, Holler E, Schwerdtfeger R, Arnold R, Scheid C, Müller-Tidow C, Woermann BJ, Hiddemann W, Berdel WE, Büchner T. Stelljes M, et al. Among authors: heinecke a. J Clin Oncol. 2014 Feb 1;32(4):288-96. doi: 10.1200/JCO.2013.50.5768. Epub 2013 Dec 23. J Clin Oncol. 2014. PMID: 24366930 Clinical Trial.
Acute myeloid leukaemia (AML): treatment of the older patient.
Büchner T, Hiddemann W, Schoch C, Haferlach T, Sauerland MC, Heinecke A. Büchner T, et al. Among authors: heinecke a. Best Pract Res Clin Haematol. 2001 Mar;14(1):139-51. doi: 10.1053/beha.2000.0120. Best Pract Res Clin Haematol. 2001. PMID: 11355928 Review.
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buchner T, Hiddemann W. Kern W, et al. Among authors: heinecke a. Blood. 2003 Jan 1;101(1):64-70. doi: 10.1182/blood-2002-02-0532. Epub 2002 Jun 28. Blood. 2003. PMID: 12393605 Free article. Clinical Trial.
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A; German AML Cooperative Group. Büchner T, et al. Among authors: heinecke a. J Clin Oncol. 2003 Dec 15;21(24):4496-504. doi: 10.1200/JCO.2003.02.133. J Clin Oncol. 2003. PMID: 14673036 Clinical Trial.
244 results